Clinical Report: The Role of γδ T Cells in Immunotherapy Approaches
Background
γδ T cells are being explored for their unique properties in immunotherapy, especially for B-cell malignancies. Understanding the mechanisms of their activation is crucial for optimizing their therapeutic use.
Data Highlights
No numerical data presented in the article.
Key Findings
γδ T cell activation is influenced by CD3, CD2, CD226, and adhesion molecules like LFA-1.
Ex vivo expanded Vγ9Vδ2 T cells modified with CARs show promise for off-the-shelf cancer immunotherapies.
Current guidelines do not recommend γδ T-cell therapies for B-cell malignancies, framing them as investigational.
Recent trials have reported response rates for CAR-γδ T-cell therapies in aggressive B-cell lymphomas.
Clinical Implications
γδ T cells have potential in immunotherapy, but their clinical application remains investigational.
Conclusion
The findings highlight the complexity of γδ T cell activation and its implications for immunotherapy.
